Posts tagged “1800PR” (Page 4)

UPDATE: DDN Storage CEO Alex Bouzari Talks Big Data and Cloud Storage Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 14th, 2015 Hosted by Michael Yorba, 1:00pm ET/10:00am PT/12:00pm CT

SANTA CLARA, CA–(Mar 13, 2015) – Alex Bouzari, co-founder and CEO of DDN Storage (DDN), the world leader in high-performance and massively scalable data storage, will talk live on Saturday, March 14, 2015 at 1pm ET with host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s, “The Trader’s Network Show.” In this exclusive interview, Bouzari will discuss the evolution of Big Data and Web/Cloud storage and reveal his vision for the future of the storage industry. He will also discuss the company’s 2014 milestones and touch on DDN’s 2015 outlook.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 14, 2015
Start Time: 1:00pm ET | 10:00am PT | 12:00pm CT
Network: Clear Channel / iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

About Alex Bouzari
Alex Bouzari is a visionary IT leader with more than 25 years of experience in founding and managing profitable, high growth technology companies. Prior to co-founding DDN — which is now the world’s largest, privately held storage company, with over 1,200 customers and 650 employees in 20 countries — Alex served as CEO of Personal Writer, Inc., and was a co-founder of MegaDrive Systems, Inc. Alex holds Bachelor of Science degrees in Engineering and Economics from the California Institute of Technology (Caltech), with graduate studies in Engineering at the Massachusetts Institute of Technology (MIT) and Stanford University.

About DDN Storage
DDN is the world leader in high-performance and massively scalable data storage. We empower Enterprises to extract maximum value from their information while accelerating bottom line results. By leveraging the best talent in the industry, DDN® Storage and Professional Services help content rich and high-growth IT environments achieve peak levels of systems scalability, performance, efficiency and simplicity. Across traditional and commercial high performance computing, our customers rely on DDN solutions to solve the most demanding big data problems in cloud, online content and social networking, security and intelligence, life sciences, finance, energy and media production. Deployed in thousands of mission critical environments worldwide, DDN engineers proven solutions for the most scalable data centers and delivers you the ultimate competitive advantage needed to succeed in today’s information-driven Enterprise.

CONTACT INFORMATION

iHeart Radio’s “HealthTech Talk” Show to Feature MYOS Corporation’s Ingredient Fortetropin™ in Exclusive Interview With Company Chairman

Dr. Robert Hariri to Be Interviewed by Ben Chodor on March 7, 2015 at 3:00pm ET/12:00pm PT/2:00pm CT

CEDAR KNOLLS, NJ–(Mar 6, 2015) – MYOS Corporation (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that its Chairman of the Board, Dr. Robert J. Hariri, will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios — 640 WGST AM tomorrow, at 3:00pm ET.

In this exclusive interview, Dr. Hariri will discuss the Company’s all-natural ingredient, Fortetropin™, the first clinically demonstrated myostatin inhibitor, and soon-to-be launched product line RE, the Company’s 2014 milestones and touch on MYOS’s 2015 outlook and the recent outspoken celebrity attention MYOS has been garnering from Justin Bieber and the world’s strongest man. Fortetropin™ is manufactured to optimize biological activity to build healthy lean muscle. MYOS believes Fortetropin™ has the potential to redefine existing standards for muscle health and human longevity.

MYOS encourages all shareholders, analysts, industry professionals and interested parties to tune in live to the interview with Dr. Hariri. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 7, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information about please visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Show
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

About Dr. Robert Hariri
Dr. Robert Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. The Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering. In addition to his role at Celgene Cellular Therapeutics, Dr. Hariri is also Vice-Chairman & Co-Founder of Human Longevity, Inc. (HLI).

His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).

Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. Dr. Hariri also serves on numerous Boards of Directors including Myos Corporation and Provista Diagnostics. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine and a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by NJ Governor Christie. Dr. Hariri is also a member of the Board of Trustees of the J. Craig Venter Institute.

A jet-rated commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri has also produced several feature films as well as documentaries on global societal issues.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as “The Muscle Company,”™ visit www.myoscorp.com.

The Company’s first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com,www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ’s continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

A 1800PublicRelations.com PR Event…

CONTACT INFORMATION

CEO Kevin Lasser of JEMS Technology to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 2:30pm ET/11:30am PT/1:30pm CT

ORION, MI–(Mar 6, 2015) – JEMS Technology, a telehealth solutions company that improves security, immediacy, quality, and mobility, announced today that Chief Executive Officer (CEO) Kevin Lasser will be featured live on Saturday, March 7, 2015 at 2:30pm ET by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network Show.” In this exclusive interview, Kevin Lasser will discuss how Healthcare providers have suffered without a reliable telemedicine system for secure real-time mobile until “The JEMS™ Mobile Health System.” The system is available everywhere, including over 3G, 4G, and “coffee shop” Wi-Fi. He will also discuss how JEMS Technology is now being utilized in non-healthcare markets.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 7, 2015
Start Time: 2:30pm ET | 11:30am PT | 1:30pm CT
Network: Clear Channel / iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Trader’s Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Trader’s Network Show
For the past six years “The Trader’s Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… Shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Trader’s Network Show.

About Kevin Lasser
Mr. Kevin Lasser has 29 years of experience in business building, finance, and technology solutions. Mr. Lasser is Chief Executive of JEMS Technology — the mobile health care solution that provides a consult anytime, anywhere. He oversees global business operations for JEMS — which is becoming the preferred telehealth choice for health care providers in North America, and Asia in both private and public institutions. Additionally, he is a committee member of the inaugural mobile health HIMSS (Healthcare Information and Management Systems Society) committee and past chair of MTAM’s (Mobile Technology Association of Michigan) mHealth Advisory Council.

Prior to JEMS, Mr. Lasser was Chief Executive Officer and co-founder of Encryption Security Solutions (ESS) and Pure Entropy Technologies (PET) where he led both companies in becoming best in class providers of encryption/cyber security solutions to private (through ESS) and public (through PET) institutions.

Prior to ESS and PET, Mr. Lasser was President and founder of Sage Financial Corporation (Sage). Sage was consistently honored with “Top Ten Money Finders Group Awards” from esteemed financial organizations such as GE Capital, Pitney Bowes Financial and Maryland National Financial Corp. Sage funded approximately $220 million for small to mid-size businesses over a ten year period.

Mr. Lasser is a well sought after key thought leader on matters of telehealth. He has spoken on many topics including “The ROI in Health Care on Mobile Devices,” “Bio Medical Wireless Technologies,” “Health Care Technology for Critical Access Facilities,” “The Impact of Mobile Devices in Healthcare,” and the recipient of numerous professional awards.

About JEMS Technology
Headquartered in Orion, Mich., JEMS Technology’s focus is simple: Consult. Anytime. Anywhere. It specializes in secure, encrypted (HIPAA compliant) real-time video to hand held devices, including the iPhone, iPad, Android-based phones and Android-based tablets. JEMS Technology is focused on the healthcare market, where remote access to secure live video can assist healthcare providers to deliver better care. From real-time video to phone connectivity, JEMS Technology is effective, easy-to-use and easy to implement.

The JEMS platform is adaptable and scalable — the JEMS suite of solutions is being utilized in various health care disciplines (tele-neurology, tele-ALS, tele-OR, tele-OB, tele-cardiology, etc….) in both private and public institutions (DHS, VA, Department of Justice). JEMS is also delivering immediate best in class health care for better outcomes from places other than health care facilities (first responder vehicles, residences, etc…).

Additionally, JEMS is now being utilized in non-healthcare markets. One such example is “tele-engineering.” Rather than travel to various manufacturing plants to repair equipment, an engineer can advise others on how to make those repairs in an immediate, efficient and secure manner from the convenience of their smart device.

For more information on JEMS Technology, visit http://www.JEMSTech.com.

A 1800PublicRelations.com PR Event…

CONTACT INFORMATION

CEO Keith Blakely of OnCore Golf Technology, Inc. to Be Interviewed on Clear Channel — iHeart Business Talk Radio’s “The Trader’s Network”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 2:00pm ET/11:00am PT/1:00pm CT

BUFFALO, NY–(Mar 6, 2015) – OnCore Golf Technology, Inc., a company that has produced the world’s first and only patented hollow-metal core golf ball, announced today that Chief Executive Officer (CEO) Keith Blakely will be interviewed live by host Michael Yorba on Clear Channel — iHeart Business Talk Radio’s “The Trader’s Network” Show. In this exclusive interview, Mr. Blakely will discuss how the company’s USGA-conforming MA-1.0 golf ball enhances the golf experience and lowers the score for anyone who uses it. U.S. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: March 7, 2015
Start Time: 2:00pm ET | 11:00am PT | 1:00pm CT (U.S.)
Network: Clear Channel – iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About OnCore Golf Technology, Inc.
OnCore Golf brings you the world’s first and only patented hollow-metal core golf ball. We understand that in golf, hitting the ball straight is paramount to scoring lower. We have designed a ball that helps you do just that and makes your game more competitive as a result.

The MA 1.0 is the most radical departure from traditional golf ball construction in over 30 years and will enhance the experience and lower the score for anyone who uses it. We can’t all hit perfect fairway shots or putt like the pros but this ball narrows the gap and will have you enjoying your game more and more.

THE CONCEPT
The proprietary alloy used in our hollow-metal core combined with ultra-high performance polymer composite blends in the mantle layer shifts the ball’s weight to the perimeter, increasing the Moment of Inertia and reducing sidespin. The result is a straighter drive, more accurate iron shots, and laser-straight putts.

THE RESULT
A product that will improve a golfer’s score from the very first time they use it, strengthening their commitment to (and the enjoyment of) the game of golf.

BUY THE MA-1.0! CLICK HERE TO SHOP ONLINE!

About CEO Keith Blakely
Keith Blakely is the Chairman and CEO of OnCore Golf Technology, Inc.. He is a two-time winner of R&D Magazines’ IR-100 award, holds multiple US patents, has appeared on CNBC’s Squawk Box, profiled in Figaro magazine, and was named Business Leader of the Year by Small Times Magazine. He is a serial entrepreneur and started his first company, Advanced Refractory Technologies, Inc. (ART) at the age of 24. He served as ART’s Chairman, President & CEO, overseeing its growth from a 2-person operation to an enterprise with over 325 people, three international joint ventures and three domestic facilities — in Buffalo, NY, Santa Clara, CA, and Amesbury, MA. During his tenure, he established strategic and commercial relationships with General Motors, Motorola, Ericsson, Bekaert, Mitsubishi, Westinghouse, Siemens, McDermott International, United Defense, and many other major international corporations. The company was recognized as a worldwide leader in advanced materials and components when it was acquired by a subsidiary of Tyco International in June, 2001.

In 2002, Blakely started NanoDynamics, Inc., a leader in the commercialization of nanomaterials and nanotechnology-enabled components and systems. He served as its CEO until 2009, raised over $60 million, and oversaw the development and launch of disruptive products for the energy, environmental, and infrastructure markets. He also established Epik Energy Solutions, LLC a $10 million joint venture with the venture arm of Shell Oil.

Blakely now provides executive leadership to several companies that are clients and investments of The InVentures Group, Inc., a venture investment and strategic advisory firm focused on delivering technology assessments, strategic business planning, and technology commercialization assistance to organizations on a global basis. InVentures has brought expertise and capital to game-changing companies in water purification (R3 Fusion), natural resources (Li3 Energy, Renew Rare Earths), advanced materials (Ceno Technologies, Nuenz, Graphene Technologies, Haydale Ltd.), medical and biotechnology (Advanced Home Telehealth, Medical Acoustics, HealtheSignals), software and financial technology (CrowdBouncer), and consumer products (OnCore Golf).

Blakely is a native of Western New York and a graduate of SUNY Buffalo. He has served as a director of numerous public and private organizations over the past three decades and is a lifelong fan of Buffalo’s professional sports teams — clear evidence of his belief that you can never give up!

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am – 7:30am and 2pm – 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show. To inquire about being a guest on this show please contact “1800pr” at www.1800PublicRelations.com.

CONTACT INFORMATION

CEO and Director Ronnie Adams of Medical Alarm Concepts to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT

KING OF PRUSSIA, PA–(Mar 6, 2015) – Medical Alarm Concepts (OTCQB:MDHI), the creator of the MediPendant® a patented two-way and three-way medical alarm, announced today that its Chief Executive Officer (CEO) and Director Ronnie Adams, will be interviewed live on Saturday, March 7, 2015 at 1:30pm ET by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network Show.” In this exclusive interview, Mr. Adams will discuss the unique features and functions of their flagship product, the MediPendant® medical alarm. He will also discuss: the iHelp™, their new mobile medical alarm (mpers). The iHelp™ is an easy to use, lightweight, yet rugged pendant, with advanced features such as a proprietary GPS tracking and a “find loved one feature” to pinpoint a user’s location, patented voice prompts so the user knows that their call has gone through, full battery supervision, and the most reliable cellular coverage and service, so the user can feel comfortable taking their iHelp™ anywhere they go.

The Company has a robust business plan for growth in the coming year and is planning several acquisitions as well as new product development and key enhancements to the existing products.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide steam are below.

Date: March 7, 2015
Start Time:  1:30pm ET | 10:30am PT | 12:30pm CT
Network: Clear Channel / iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

About CEO and Director Ronnie Adams
Ronnie Adams is the Company’s CEO and Director. He has also served as President and Chief Financial Officer of a NASDAQ company that he started from inception and grew to over $60 million. Mr. Adams was the recipient of the prestigious Entrepreneur of the Year Award in 1996, sponsored by Dow Jones, NASDAQ and Ernst & Young.

About Medical Alarm Concepts
Medical Alarm Concepts Holding, Inc., a publicly traded company under the symbol MDHI, is the creator of the MediPendant® a patented two-way and three-way medical alarm, as well as the iHelp™ mobile medical alert, a state-of-the-art mobile personal emergency response system (mPERS). The MediPendant® has been featured in nationally renowned retailer Costco Wholesale Corporation since 2011 and has received 28 product reviews on the retailer’s website, 21 of which are “5 out of 5 Star” ratings. The average rating is “4.5 Stars out of 5 Stars.”

A 1800PublicRelations.com PR Event…

CONTACT INFORMATION

CEO Tom Brophy of CUR Media, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 1:00pm ET/10:00am PT/12:00pm CT

GLASTONBURY, CT–(Marketwired – Mar 6, 2015) – CÜR Media, Inc. (OTCQB: CURM) (OTCBB: CURM) announced today that Founder and Chief Executive Officer (CEO) Tom Brophy will be interviewed live tomorrow by host Michael Yorba on Clear Channel — iHeart Business Talk Radio’s, “The Trader’s Network Show.”

In this exclusive double-segment interview, Mr. Brophy will discuss how CÜR Media is developing a next generation social music experience through the planned launch of CÜR Music, a social streaming music application and website that is being designed to enable its users to go beyond the limitations of traditional music streaming services. He will also discuss recent business developments that will shape the planned launch of CÜR Music later this year in the multi-billion dollar music industry.

All Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s iHeart Radio stream.

Date: March 7, 2015
Start Time: 1:00pm ET | 10:00am PT | 12:00pm CT (U.S.)
Network: Clear Channel — iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About CÜR Media
CÜR Media is creating a next generation social music experience through the planned launch of CÜR Music, a social streaming music application and website that is being designed to enable its users to go beyond the limitations of traditional music streaming services. CÜR Music will unlock the true expressive nature of an individual’s connection with their music by fostering personalization, sharing and creativity. With CÜR Music it’s not just about streaming, it’s about what the music means to you and how you want to express that to the world. For more information please visit www.curmusic.com.

About CEO Tom Brophy
Mr. Brophy has been involved in Executive roles of start-ups and growth companies since 1994. Mr. Brophy was the CFO of Interactive Search Holdings, the first company to mass distribute search toolbars across the web, pioneering the search toolbar business which became a multi-billion dollar industry. The Company was also the first company to mass distribute smiley emoticons as part of its toolbar distribution strategy. Mr. Brophy started his career at Deloitte & Touche, has been the Chief Financial Officer of several startup and growth companies and has several successful exits. He has also been the Chief Financial Officer of a public company.

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more. Shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of a commercially viable streaming music product, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the Company’s ability to negotiate economically feasible agreements with the major and independent music labels and publisher rights organizations, and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) and (v) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the length of time associated with development of mobile applications and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies.

A 1800PublicRelations.com PR Event.

CONTACT INFORMATION

CEO & Chairman Ted William Karkus of ProPhase Labs, Inc. to Be Interviewed Live on Clear Channel – iHeart Business Talk Radio’s “Health Tech Talk Live”

Live Interview Airs Saturday, February 28th, 2015, 3:00pm ET/12:00pm PT/2:00pm CT

DOYLESTOWN, PA–(Feb 27, 2015) – ProPhase Labs, Inc. (NASDAQ: PRPH), a company that engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public, announced today that CEO & Chairman Ted William Karkus will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive 2-segment interview, Mr. Karkus will discuss the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care and cosmeceutical products. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About ProPhase Labs, Inc.
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® Cold Remedy brand as well as other cold relief products. Cold-EEZE®Cold Remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE® Cold Remedy customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE®Cold Remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Forward Looking Information
Except for the historical information contained herein or discussed on air on February 28, 2015, this document and our on-air discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air on February 28th, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

HAYWARD, CA–(Feb 27, 2015) – Aradigm Corporation (NASDAQ: ARDM), a company actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease, announced today that President and Chief Executive Officer (CEO) Dr. Igor Gonda, Ph.D. will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive double-segment interview, Dr. Gonda will discuss how the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products like AERx®, a pulmonary delivery platform.

Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Aradigm Corporation
Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease.

Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team for example, pioneered the AERx® pulmonary delivery platform that was tested in thousands of patients with drugs and biologics including insulin, fentanyl, erythropoietin and nicotine. With the depth of experience and expertise in inhalation delivery, Aradigm is uniquely positioned to develop a portfolio of its own products to treat patients with severe respiratory diseases. The current pipeline includes an inhaled antibiotic being developed for the treatment of bronchiectasis*, cystic fibrosis and for biodefense, and inhaled nicotine for smoking cessation.

About President and CEO Dr. Igor Gonda, Ph.D.
Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

Chairman & CEO Rik J. Deitsch of Nutra Pharma Corporation to Be Interviewed Live on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air February 21, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

CORAL SPRINGS, FL–(Feb 20, 2015) – Nutra Pharma Corporation (OTC PINK: NPHC), a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases, announced today that Chairman and Chief Executive Officer (CEO) Rik J. Deitsch will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Mr. Deitsch will discuss how Nutra Pharma is currently expanding its OTC retail sales of their pain therapies: Nyloxin® and Pet Pain-Away. He also discusses the clinical development of its first two therapeutic products. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 21, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company currently markets drug products for the treatment of pain under the brands Nyloxin® and Pet Pain-Away.

About CEO Rik J. Deitsch
Nutra Pharma’s Chairman and Chief Executive Officer holds both a B.S. in Chemistry and an M.S. in Biochemistry and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is the author of two books: Are You AgeWise: A Guide to Healthy Aging, and Invisible Killers: the Truth About Environmental Genocide. He is also an adjunct professor, teaching several courses for Florida Atlantic University’s College of Business and Continuing Education Department.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com. If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

 

Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live” on February 14, 2015

Live Interview Airs on “Health Tech Talk Live,” Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

ATLANTA, GA–(Feb 13, 2015) – Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel®, the company’s development of the world’s first antiviral condom (the VivaGel® condom) which was recently launched in Australia by Starpharma’s partner, Ansell. Dr Fairley will also talk about Starpharma’s current US Phase III clinical trials of VivaGel® for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company’s improved version of cancer drug docetaxel (Taxotere). The Company’s product, DEP™ docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP™ docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere® and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup®) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 14, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers — a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer. VivaGel® formulated as a mucoadhesive gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate license agreements with Ansell Limited (ASX: ANN) and Okamoto Industries Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®) which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals, Starpharma has a series of partnerships with leading industry players, as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Starpharma’s headquarters and research facilities are located in Melbourne, Australia. Starpharma principally consists of two operating companies, Starpharma Pty Ltd in Australia and Dendritic Nanotechnologies, Inc. in USA, both with a comprehensive intellectual property portfolio.

Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX: SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.

About CEO Dr. Jackie Fairley B.Sc., B.V.Sc. (Hons), MBA

Jackie Fairley has 25 years of operational experience in the pharmaceutical and biotechnology industries working as a CEO since 2000. Prior to that she held business development, licensing and general management roles with companies including CSL and Faulding (now Hospira).

In 2006, Jackie was appointed CEO of ASX-listed biotechnology company Starpharma Holdings. Under her leadership, the company has been promoted to the ASX300, has developed several new and valuable commercial applications for its proprietary polymer technology and signed a number of strategically important commercial deals with companies including Astra Zeneca, Okamoto and Ansell. Starpharma has also significantly strengthened its institutional shareholder base, attracting investment from major European, US and Asian funds.

Jackie holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School, where as top student in her final year, she was the recipient of the prestigious Clemenger Medal. Jackie is also a Graduate of the Australian Institute of Company Directors.

In addition to her role at Starpharma, Jackie has served on the Board of the Melbourne Business School since 2010 and sits on the Investment Committee of Mark Carnegie’s Innovation Fund. She also sits on a number of specialist Government advisory committees.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2766291
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2766293

Interview Press/ Media  
Matthew BIRD
President
1-800-PublicRelations
+1 (917) 409-8211
matt.bird@1800pr.com
www.1800pr.com
Visit Our BlogVisit Our BlogVisit Our Blog